2,338 results on '"Kalafat, E."'
Search Results
2. Can endometrial compaction predict live birth rates in assisted reproductive technology cycles? A systematic review and meta-analysis
- Author
-
Turkgeldi, E., Yildiz, S, Kalafat, E., Keles, I., Ata, B., and Bozdag, G.
- Published
- 2023
- Full Text
- View/download PDF
3. Ongoing pregnancy rates in single euploid frozen embryo transfers remain unaffected by female age: a retrospective study
- Author
-
Lawrenz, B., Kalafat, E., Ata, B., Gallego, R. Del, Melado, L., Bayram, A., Elkhatib, I., and Fatemi, H.
- Published
- 2024
- Full Text
- View/download PDF
4. Walking on thin endometrium.
- Author
-
Ata B, Mathyk B, Telek S, and Kalafat E
- Subjects
- Female, Humans, Pregnancy, Reproductive Techniques, Assisted, Ultrasonography, Embryo Implantation physiology, Embryo Transfer methods, Endometrium diagnostic imaging
- Abstract
Purpose of Review: Endometrial thickness has been regarded a predictor of success in assisted reproductive technology cycles and it seems a common practice to cancel embryo transfer when it is below a cut-off. However, various cut-offs have been proposed without a causal relationship between endometrial thickness and embryo implantation being established, casting doubt on the current dogma., Recent Findings: Methodological limitations of the available studies on endometrial thickness are increasingly recognized and better designed studies do not demonstrate a cut-off value which requires cancelling an embryo transfer., Summary: Endometrium is important for implantation and a healthy pregnancy; however, ultrasound measured thickness does not seem to be a good marker of endometrial function., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
5. Neutralizing antibody levels and cellular immune response against Omicron variant in pregnant women vaccinated with mRNA and inactivated SARS-CoV-2 vaccines.
- Author
-
Kalafat E, Talay ZG, Demirci O, Ayaz R, Çelik E, and Can F
- Subjects
- Humans, Female, Pregnancy, Adult, Antibodies, Viral blood, Immunity, Cellular, Pregnancy Complications, Infectious immunology, Pregnancy Complications, Infectious prevention & control, Pregnancy Complications, Infectious virology, mRNA Vaccines, COVID-19 Vaccines immunology, SARS-CoV-2 immunology, COVID-19 prevention & control, COVID-19 immunology, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Vaccines, Inactivated immunology
- Published
- 2024
- Full Text
- View/download PDF
6. Association between fetal growth restriction and stillbirth in twin compared with singleton pregnancies.
- Author
-
Martínez-Varea A, Prasad S, Domenech J, Kalafat E, Morales-Roselló J, and Khalil A
- Subjects
- Humans, Female, Pregnancy, Retrospective Studies, Cross-Sectional Studies, Adult, Infant, Newborn, Birth Weight, London epidemiology, Risk Factors, Stillbirth epidemiology, Fetal Growth Retardation epidemiology, Pregnancy, Twin statistics & numerical data, Infant, Small for Gestational Age, Gestational Age
- Abstract
Objectives: Twin pregnancies are at higher risk of stillbirth compared to singletons. Fetal growth restriction (FGR) is a major cause of perinatal mortality, but its impact on twins vs singletons remains unclear. The primary objective of this study was to investigate the association of FGR and small-for-gestational age (SGA) with stillbirth in twin compared with singleton pregnancies. A secondary objective was to assess these associations stratified by gestational age at delivery. Furthermore, we aimed to compare the associations of FGR and SGA with stillbirth in twin pregnancies using twin-specific vs singleton birth-weight charts, stratified by chorionicity., Methods: This was a retrospective cross-sectional study of pregnancies receiving obstetric care and giving birth between 1999 and 2022 at St George's Hospital, London, UK. The exclusion criteria included triplet and higher-order pregnancies, those resulting in miscarriage or live birth at ≤ 23 + 6 weeks, termination of pregnancy and missing data regarding birth weight or gestational age at birth. Birth-weight data were collected and FGR and SGA were defined as birth weight <5
th and <10th centiles, respectively. While standard logistic regression was used for singleton pregnancies, the association of FGR and SGA with stillbirth in twin pregnancies was investigated using mixed-effects logistic regression models. For twin pregnancies, intercepts were allowed to vary for twin pairs to account for intertwin dependency. Analyses were stratified by gestational age at delivery and chorionicity. Statistical significance was set at P ≤ 0.001., Results: The study included 95 342 singleton and 3576 twin pregnancies. There were 494 (0.52%) stillbirths in singleton and 41 (1.15%) stillbirths in twin pregnancies (17 dichorionic and 24 monochorionic). SGA and FGR were associated significantly with stillbirth in singleton pregnancies across all gestational ages at delivery: the odds ratios (ORs) for SGA and FGR were 2.36 ((95% CI, 1.78-3.13), P < 0.001) and 2.67 ((95% CI, 2.02-3.55), P < 0.001), respectively, for delivery before 32 weeks; 2.70 ((95% CI, 1.71-4.31), P < 0.001) and 2.82 ((95% CI, 1.78-4.47), P < 0.001), respectively, for delivery between 32 and 36 weeks; and 3.85 ((95% CI, 2.83-5.21), P < 0.001) and 4.43 ((95% CI, 3.16-6.12), P < 0.001), respectively, for delivery after 36 weeks. In twin pregnancies, when stratified by gestational age at delivery, both SGA and FGR determined by twin-specific birth-weight charts were associated with increased odds of stillbirth for those delivered before 32 weeks (SGA: OR, 3.87 (95% CI, 1.56-9.50), P = 0.003 and FGR: OR, 5.26 (95% CI, 2.11-13.01), P = 0.001), those delivered between 32 and 36 weeks (SGA: OR, 6.67 (95% CI, 2.11-20.41), P = 0.001 and FGR: OR, 9.54 (95% CI, 3.01-29.40), P < 0.001) and those delivered beyond 36 weeks (SGA: OR, 12.68 (95% CI, 2.47-58.15), P = 0.001 and FGR: OR, 23.84 (95% CI, 4.62-110.25), P < 0.001). However, the association of stillbirth with SGA and FGR in twin pregnancies was non-significant when diagnosis was based on singleton charts (before 32 weeks: SGA, P = 0.014 and FGR, P = 0.005; 32-36 weeks: SGA, P = 0.036 and FGR, P = 0.008; after 36 weeks: SGA, P = 0.080 and FGR, P = 0.063)., Conclusion: Our study demonstrates that SGA and, especially, FGR are associated significantly with an increased risk of stillbirth across all gestational ages in singleton pregnancies, and in twin pregnancies when twin-specific birth-weight charts are used. © 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., (© 2024 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.)- Published
- 2024
- Full Text
- View/download PDF
7. Machine learning prediction of hypertension and diabetes in twin pregnancies using characteristics at prenatal care entry: a nationwide study
- Author
-
Mustafa, H. J., primary, Kalafat, E., additional, Prasad, S., additional, Heydari, M. ‐H., additional, Nunge, R. N., additional, and Khalil, A., additional
- Published
- 2024
- Full Text
- View/download PDF
8. Undetected, natural conception pregnancies in luteal phase stimulations—case series and review of literature.
- Author
-
Lawrenz, B, Ata, B, Kalafat, E, Gallego, R Del, Selim, S, Edades, J, and Fatemi, H
- Abstract
STUDY QUESTION What is the risk of an undetected natural conception pregnancy during luteal phase ovarian stimulation, and how does it impact the pregnancy's course? SUMMARY ANSWER The risk for an undetected, natural conception pregnancy in luteal phase ovarian stimulation is low and it appears that ovarian stimulation is unlikely to harm the pregnancy. WHAT IS KNOWN ALREADY Random start ovarian stimulation appears to be similarly effective as early follicular stimulation start; and it allows ovarian stimulation to be started independent of the cycle day and throughout the cycle, in accordance with the patients' and clinics' schedule as long as there is no intention of a fresh embryo transfer in the same cycle. Starting ovarian stimulation in the luteal phase bears the possibility of an—at the timepoint of stimulation start—undetected, natural conception pregnancy that has already occurred. There is scarce data on the incidence of this event as well as on the possible implications of ovarian stimulation on the course of an existing pregnancy. STUDY DESIGN, SIZE, DURATION This retrospective observational study, performed between June 2017 and January 2024, analyzed luteal phase stimulations, in which a natural conception pregnancy was detected during the ovarian stimulation treatment for IVF/ICSI. Luteal phase stimulation was defined as ovarian stimulation started after ovulation and before the next expected menstrual bleeding, with a serum progesterone (P4) level of >1.5 ng/ml on the day of stimulation start or 1 day before. PARTICIPANTS/MATERIALS, SETTING, METHODS Women who underwent a luteal phase ovarian stimulation in a tertiary referral ART center. MAIN RESULTS AND THE ROLE OF CHANCE A total of 488 luteal phase stimulation cycles were included in the analysis. Luteal phase stimulation was only started after a negative serum hCG measurement on the day or 1 day before commencement of ovarian stimulation. Ten patients (2.1%) had an undetected natural conception pregnancy at the time of luteal phase stimulation start. Eight of these patients underwent an ovarian stimulation in a GnRH-antagonist protocol and two in a progestin-primed stimulation protocol (PPOS). Recombinant FSH was used as stimulation medication for all patients, the patients with a PPOS protocol received additional recombinant LH. One pregnancy (0.2%) was detected after the oocyte retrieval, the other nine pregnancies were detected either due to persistent high serum progesterone levels or due to an increasing progesterone level after an initial decrease before oocyte retrieval. In the cycles with an undetected natural conception pregnancy, the median number of stimulation days was 8 days (range: 6–11 days) and median serum hCG at detection of pregnancy was 59 IU hCG (range: 14.91–183.1). From 10 patients with a pregnancy, three patients delivered a healthy baby, two patients had ongoing pregnancies at the time of summarizing the data, three patients had biochemical pregnancies (patient age: 30, 39, and 42 years), one patient had an ectopic pregnancy which required a salpingectomy, and one patient (age: 34 years) had an early pregnancy loss. LIMITATIONS, REASONS FOR CAUTION The retrospective study design and the small sample size can limit the accuracy of the estimates. WIDER IMPLICATIONS OF THE FINDINGS Overall, there is a small risk of undetected natural conception pregnancies when luteal phase stimulation is undertaken. It appears that there are no adverse effects through either direct effect on the embryo or indirectly through a detrimental effect on the corpus luteum function on the pregnancy in our cohort. STUDY FUNDING/COMPETING INTEREST(S) This study did not receive funding. The authors declare that there is no conflict of interest. TRIAL REGISTRATION NUMBER N/A. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Do women with severely diminished ovarian reserve undergoing modified natural‐cycle in‐vitro fertilization benefit from earlier trigger at smaller follicle size?
- Author
-
Lawrenz, B., Kalafat, E., Ata, B., Melado, L., Del Gallego, R., Elkhatib, I., and Fatemi, H.
- Subjects
- *
OVARIAN reserve , *INDUCED ovulation , *MENSTRUAL cycle , *OVUM , *OVULATION - Abstract
Objective: To evaluate whether trigger and oocyte collection at a smaller follicle size decreases the risk of premature ovulation while maintaining the reproductive potential of oocytes in women with a severely diminished ovarian reserve undergoing modified natural‐cycle in‐vitro fertilization. Methods: This was a retrospective cohort study including women who had at least one unsuccessful cycle (due to no response) of conventional ovarian stimulation with a high dosage of gonadotropins and subsequently underwent a modified natural cycle with a solitary growing follicle (i.e. only one follicle > 10 mm at the time of trigger). The association between follicle size at trigger and various cycle outcomes was tested using regression analyses. Results: A total of 160 ovarian stimulation cycles from 110 patients were included in the analysis. Oocyte pick‐up (OPU) was performed in 153 cycles and 7 cycles were canceled due to premature ovulation. Patients who received their trigger at smaller follicle sizes (≤ 15 mm) had significantly lower rates of premature ovulation and thus higher rates of OPU (98.9% vs 90.8%; odds ratio, 9.56 (95% CI, 1.58–182.9); P = 0.039) compared with those who received their trigger at larger follicle sizes (> 15 mm). On multivariable analysis, smaller follicle sizes at trigger (> 10 to 13 mm, > 13 to 15 mm, > 15 mm to 17 mm) were not associated significantly with a lower rate of cumulus–oocyte complex (COC) retrieval, metaphase‐II (MII) oocytes or blastulation when compared to the > 17‐mm group. On sensitivity analysis including only the first cycle of each couple, the maturity rate among those with COC retrieval was highest in follicle sizes > 15 to 17 mm (92.3%) and > 13 to 15 mm (91.7%), followed by > 10 to 13 mm (85.7%) and lowest in the > 17‐mm group (58.8%). During the study period, five euploid blastocysts developed from 48 fertilized MII oocytes with follicle sizes of 12 mm (n = 3), 14 mm (n = 1) and 16 mm (n = 1) at trigger. Of those, four were transferred and resulted in two live births, both of which developed from follicles with a size at trigger of 12 mm. Conclusions: The ideal follicle size for triggering oocyte maturation may be smaller in women with a severely diminished ovarian reserve managed on a modified natural cycle when compared to conventional cut‐offs. The risk of OPU cancellation was significantly higher in women triggered at follicle size > 15 mm and the yield of mature oocytes was not adversely affected in women triggered at follicle size > 13 to 15 mm compared with > 15 to 17 mm. Waiting for follicles to reach sizes > 17mm may be detrimental to achieving optimal outcome. © 2024 International Society of Ultrasound in Obstetrics and Gynecology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Do women with severely diminished ovarian reserve undergoing modified natural cycles benefit from earlier trigger at smaller follicle size?
- Author
-
Lawrenz, B., primary, Kalafat, E., additional, Ata, B., additional, Melado, L., additional, Del Gallego, R., additional, Elkhatib, I., additional, and Fatemi, H., additional
- Published
- 2024
- Full Text
- View/download PDF
11. COVID-19 Vaccination During Pregnancy: Coverage and Safety
- Author
-
Blakeway, H., Prasad, S., Kalafat, E., Heath, P.T., Ladhani, S.N., Le Doare, K., Magee, L.A., O’Brien, P., Rezvan, A., von Dadelszen, P., and Khalil, A.
- Published
- 2022
- Full Text
- View/download PDF
12. Risk factors associated with stillbirth and adverse perinatal outcomes in dichorionic twin pregnancies complicated by selective fetal growth restriction: a cohort study.
- Author
-
Kalafat E, Liu B, Barratt I, Bhate R, Papageorghiou A, and Khalil A
- Subjects
- Pregnancy, Infant, Newborn, Female, Humans, Fetal Growth Retardation epidemiology, Fetal Growth Retardation etiology, Cohort Studies, Retrospective Studies, Risk Factors, Pregnancy Outcome epidemiology, Pregnancy, Twin, Stillbirth epidemiology
- Abstract
Objective: The main aim of this study was to investigate the perinatal outcomes of dichorionic twin pregnancies complicated by selective fetal growth restriction (sFGR)., Design: Retrospective cohort study., Setting: Tertiary reference centre., Population: Dichorionic twin pregnancies complicated by sFGR between 2000 and 2019 in St George's University Hospital., Methods: Regression analyses were performed using generalised linear models and mixed-effects generalised linear models where appropriate to account for pregnancy level dependency in variables. Time to event analyses were performed with mixed-effects Cox regression models., Main Outcome Measures: Stillbirth, neonatal death or neonatal unit admission with morbidity in one or both twins., Results: A total of 102 (of 2431 dichorionic twin pregnancies) pregnancies complicated by sFGR were included in the study. The Cochrane-Armitage test revealed a significant trend for increased adverse perinatal outcome rates with more severe forms of umbilical artery flow impedance, i.e. reversed, absent, positive with resistant flow and positive flow without resistance. A multivariable model including maternal and conception characteristics had poor predictive accuracy for stillbirth (area under the curve: 0.68, 95% confidence interval [CI] 0.55-0.81) and composite adverse perinatal outcomes (area under the curve: 0.58, 95% CI 0.47-0.70). When umbilical artery Doppler parameters were added to the models, the area under the curve values improved to 0.95 (95% CI 0.89-0.99) and 0.83 (95% CI 0.73-0.92) for stillbirth and composite adverse perinatal outcomes, respectively., Conclusion: In dichorionic twin pregnancies complicated by sFGR, the umbilical artery Z-scores were associated with both intrauterine death and adverse perinatal outcomes., (© 2023 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
13. Longitudinal assessment of angiogenic markers in prediction of adverse outcome in women with confirmed pre-eclampsia.
- Author
-
Binder J, Palmrich P, Kalafat E, Haberl C, Schirwani N, Pateisky P, and Khalil A
- Subjects
- Pregnancy, Female, Humans, Infant, Newborn, Placenta Growth Factor, Retrospective Studies, Creatinine, Placenta metabolism, Biomarkers, Vascular Endothelial Growth Factor Receptor-1, Predictive Value of Tests, Pre-Eclampsia
- Abstract
Objectives: Angiogenic marker assessment, such as the ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF), is known to be a useful tool in the prediction of pre-eclampsia (PE). However, evidence from surveillance strategies in pregnancies with a PE diagnosis is lacking. Therefore, we aimed to assess the predictive performance of longitudinal maternal serum angiogenic marker assessment for both maternal and perinatal adverse outcomes when compared to standard laboratory parameters in pregnancies with confirmed PE., Methods: This was a retrospective analysis of prospectively collected data from January 2013 to December 2020 at the Medical University of Vienna. The inclusion criteria were singleton pregnancy with confirmed PE and post-diagnosis maternal serum angiogenic marker assessment at a minimum of two timepoints. The primary outcome was the predictive performance of longitudinal sFlt-1 and PlGF assessment for adverse maternal and perinatal outcomes compared to conventional laboratory monitoring at the same time in pregnancies with confirmed PE. Composite adverse maternal outcome included intensive care unit admission, pulmonary edema, eclampsia and/or death. Composite adverse perinatal outcome included stillbirth, neonatal death, placental abruption, neonatal intensive care unit admission, intraventricular hemorrhage, necrotizing enterocolitis, respiratory distress syndrome and/or mechanical ventilator support., Results: In total, 885 post-diagnosis sFlt-1/PlGF ratio measurements were obtained from 323 pregnant women with confirmed PE. For composite adverse maternal outcome, the highest standalone predictive accuracy was obtained using maternal serum sFlt-1/PlGF ratio (area under the receiver-operating-characteristics curve (AUC), 0.72 (95% CI, 0.62-0.81)), creatinine (AUC, 0.71 (95% CI, 0.62-0.81)) and lactate dehydrogenase (LDH) levels (AUC, 0.73 (95% CI, 0.65-0.81)). Maternal platelet levels (AUC, 0.65 (95% CI, 0.55-0.74)), serum alanine aminotransferase (ALT) (AUC, 0.59 (95% CI, 0.49-0.69)) and aspartate aminotransferase (AST) (AUC, 0.61 (95% CI, 0.51-0.71) levels had poor standalone predictive accuracy. The best prediction model consisted of a combination of maternal serum LDH, creatinine levels and sFlt-1/PlGF ratio, which had an AUC of 0.77 (95% CI, 0.68-0.85), significantly higher than sFlt-1/PlGF ratio alone (P = 0.037). For composite adverse perinatal outcome, the highest standalone predictive accuracy was obtained using maternal serum sFlt-1/PlGF ratio (AUC, 0.82 (95% CI, 0.75-0.89)) and creatinine (AUC, 0.74 (95% CI, 0.67-0.80)) levels, sFlt-1/PlGF ratio being superior to creatinine alone (P < 0.001). Maternal serum LDH levels (AUC, 0.65 (95% CI, 0.53-0.74)), platelet count (AUC, 0.57 (95% CI, 0.44-0.67)), ALT (AUC, 0.58 (95% CI, 0.48-0.67)) and AST (AUC, 0.58 (95% CI, 0.48-0.67)) levels had poor standalone predictive accuracy. No combination of biomarkers was superior to maternal serum sFlt-1/PlGF ratio alone for prediction of composite adverse perinatal outcome (P > 0.05 for all)., Conclusions: In pregnancies with confirmed PE, longitudinal maternal serum angiogenic marker assessment is a good predictor of adverse maternal and perinatal outcomes and superior to some conventional laboratory parameters. Further studies should focus on optimal surveillance following diagnosis of PE. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., (© 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.)
- Published
- 2023
- Full Text
- View/download PDF
14. Maternal vaccination against COVID-19 and neonatal outcomes during Omicron: INTERCOVID-2022 study.
- Author
-
Barros FC, Gunier RB, Rego A, Sentilhes L, Rauch S, Gandino S, Teji JS, Thornton JG, Kachikis AB, Nieto R, Craik R, Cavoretto PI, Winsey A, Roggero P, Rodriguez GB, Savasi V, Kalafat E, Giuliani F, Fabre M, Benski AC, Coronado-Zarco IA, Livio S, Ostrovska A, Maiz N, Castedo Camacho FR, Peterson A, Deruelle P, Giudice C, Casale RA, Salomon LJ, Soto Conti CP, Prefumo F, Mohamed Elbayoumy EZ, Vale M, Hernández V, Chandler K, Risso M, Marler E, Cáceres DM, Crespo GA, Ernawati E, Lipschuetz M, Ariff S, Takahashi K, Vecchiarelli C, Hubka T, Ikenoue S, Tavchioska G, Bako B, Ayede AI, Eskenazi B, Bhutta ZA, Kennedy SH, Papageorghiou AT, and Villar J
- Subjects
- Humans, Female, Pregnancy, Infant, Newborn, Adult, Prospective Studies, Vaccination, Pregnancy Outcome, Premature Birth epidemiology, Premature Birth prevention & control, Vaccine Efficacy, COVID-19 prevention & control, COVID-19 epidemiology, COVID-19 Vaccines, Pregnancy Complications, Infectious prevention & control, Pregnancy Complications, Infectious epidemiology, SARS-CoV-2 immunology
- Abstract
Background: In early 2023, when Omicron was the variant of concern, we showed that vaccinating pregnant women decreased the risk for severe COVID-19-related complications and maternal morbidity and mortality., Objective: This study aimed to analyze the impact of COVID-19 during pregnancy on newborns and the effects of maternal COVID-19 vaccination on neonatal outcomes when Omicron was the variant of concern., Study Design: INTERCOVID-2022 was a large, prospective, observational study, conducted in 40 hospitals across 18 countries, from November 27, 2021 (the day after the World Health Organization declared Omicron the variant of concern) to June 30, 2022, to assess the effect of COVID-19 in pregnancy on maternal and neonatal outcomes and to assess vaccine effectiveness. Women diagnosed with laboratory-confirmed COVID-19 during pregnancy were compared with 2 nondiagnosed, unmatched women recruited concomitantly and consecutively during pregnancy or at delivery. Mother-newborn dyads were followed until hospital discharge. The primary outcomes were a neonatal positive test for COVID-19, severe neonatal morbidity index, severe perinatal morbidity and mortality index, preterm birth, neonatal death, referral to neonatal intensive care unit, and diseases during the neonatal period. Vaccine effectiveness was estimated with adjustment for maternal risk profile., Results: We enrolled 4707 neonates born to 1577 (33.5%) mothers diagnosed with COVID-19 and 3130 (66.5%) nondiagnosed mothers. Among the diagnosed mothers, 642 (40.7%) were not vaccinated, 147 (9.3%) were partially vaccinated, 551 (34.9%) were completely vaccinated, and 237 (15.0%) also had a booster vaccine. Neonates of booster-vaccinated mothers had less than half (relative risk, 0.46; 95% confidence interval, 0.23-0.91) the risk of being diagnosed with COVID-19 when compared with those of unvaccinated mothers; they also had the lowest rates of preterm birth, medically indicated preterm birth, respiratory distress syndrome, and number of days in the neonatal intensive care unit. Newborns of unvaccinated mothers had double the risk for neonatal death (relative risk, 2.06; 95% confidence interval, 1.06-4.00) when compared with those of nondiagnosed mothers. Vaccination was not associated with any congenital malformations. Although all vaccines provided protection against neonatal test positivity, newborns of booster-vaccinated mothers had the highest vaccine effectiveness (64%; 95% confidence interval, 10%-86%). Vaccine effectiveness was not as high for messenger RNA vaccines only. Vaccine effectiveness against moderate or severe neonatal outcomes was much lower, namely 13% in the booster-vaccinated group (all vaccines) and 25% and 28% in the completely and booster-vaccinated groups, respectively (messenger RNA vaccines only). Vaccines were fairly effective in protecting neonates when given to pregnant women ≤100 days (14 weeks) before birth; thereafter, the risk increased and was much higher after 200 days (29 weeks). Finally, none of the neonatal practices studied, including skin-to-skin contact and direct breastfeeding, increased the risk for infecting newborns., Conclusion: When Omicron was the variant of concern, newborns of unvaccinated mothers had an increased risk for neonatal death. Neonates of vaccinated mothers had a decreased risk for preterm birth and adverse neonatal outcomes. Because the protective effect of COVID-19 vaccination decreases with time, to ensure that newborns are maximally protected against COVID-19, mothers should receive a vaccine or booster dose no more than 14 weeks before the expected date of delivery., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Is micronized vaginal progesterone effective for the prevention of preeclampsia in twin pregnancies?
- Author
-
Yaghi O, Prasad S, Boorman H, Kalafat E, and Khalil A
- Subjects
- Humans, Female, Pregnancy, Administration, Intravaginal, Pre-Eclampsia prevention & control, Progesterone administration & dosage, Progesterone therapeutic use, Pregnancy, Twin, Progestins administration & dosage, Progestins therapeutic use
- Published
- 2024
- Full Text
- View/download PDF
16. Prognostic value of angiogenic markers in pregnancy with fetal growth restriction.
- Author
-
Palmrich, P., Kalafat, E., Pateisky, P., Schirwani‐Hartl, N., Haberl, C., Herrmann, C., Khalil, A., and Binder, J.
- Subjects
- *
FETAL growth retardation , *ECLAMPSIA , *PROGNOSIS , *PLACENTAL growth factor , *DELPHI method , *PREGNANCY - Abstract
Objective: Pregnancies with fetal growth restriction (FGR) are at increased risk for pre‐eclampsia. Angiogenic markers including soluble fms‐like tyrosine kinase‐1 (sFlt‐1) and placental growth factor (PlGF) are altered in pregnancies complicated by FGR, but their utility for predicting pre‐eclampsia in growth‐restricted pregnancies is uncertain. This study aimed to evaluate the prognostic value of angiogenic markers for predicting the development of pre‐eclampsia in pregnancies with FGR and suspected pre‐eclampsia. Methods: This was a retrospective study of singleton pregnancies with FGR, defined according to Delphi consensus criteria, which underwent sampling of sFlt‐1 and PlGF for suspicion of pre‐eclampsia at the Medical University of Vienna, Vienna, Austria, between 2013 and 2020. Women with an established diagnosis of pre‐eclampsia at sampling were excluded. Cox regression analysis and logistic regression analysis were performed to evaluate the association of angiogenic markers with the development of pre‐eclampsia at various timepoints. Results: In this cohort of 93 women, pre‐eclampsia was diagnosed in 14 (15.1%) women within 1 week after sampling, 21 (22.6%) within 2 weeks after sampling and 38 (40.9%) at any time after assessment. The sFlt‐1/PlGF ratio consistently showed a stronger association with the development of pre‐eclampsia compared to sFlt‐1 or PlGF alone (pre‐eclampsia within 1 week: area under the receiver‐operating‐characteristics curve, 0.87 vs 0.82 vs 0.72). Models including the sFlt‐1/PlGF ratio were associated more strongly with pre‐eclampsia hazard compared to models including sFlt‐1 or PlGF alone (concordance index, 0.790 vs 0.759 vs 0.755). The risk classification capability of the sFlt‐1/PlGF ratio decreased after the 2‐week timepoint. The established cut‐off value for the sFlt‐1/PlGF ratio of < 38 was effective for ruling out pre‐eclampsia within 2 weeks, with a negative predictive value of 0.933 and sensitivity of 0.952. Conclusions: Use of the sFlt‐1/PlGF ratio is preferrable to the use of PlGF alone for the prediction of pre‐eclampsia in pregnancies with FGR. Established cut‐offs for ruling out the development of pre‐eclampsia in the short term seem to be effective in these patients. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Incidence of Postpartum Hypertension Within 2 Years of a Pregnancy Complicated by Preeclampsia: A Systematic Review and Meta-Analysis
- Author
-
Giorgione, V., Ridder, A., Kalafat, E., Khalil, A., and Thilaganathan, B.
- Published
- 2021
- Full Text
- View/download PDF
18. Blastocyst re-expansion 1 hour after biopsy: an independent predictor of live birth.
- Author
-
Elkhatib I, Nogueira D, Bayram A, Abdala A, Gonzales R, Del Gallego R, Ata B, Lawrenz B, Kalafat E, and Fatemi H
- Abstract
Competing Interests: Declaration of Interests None of the co-authors have conflict of interest to disclose pertaining to the subject of the study.
- Published
- 2024
- Full Text
- View/download PDF
19. Does the holy grail of the evidence pyramid vindicate the controversial practice of endometrial scratching or is there room for healthy skepticism?
- Author
-
Ata B and Kalafat E
- Published
- 2024
- Full Text
- View/download PDF
20. Response to: Cumulative live birth rate following progestin-primed ovarian stimulation: controversial results with own and donated oocytes.
- Author
-
Ata B and Kalafat E
- Subjects
- Humans, Female, Pregnancy, Live Birth, Birth Rate, Oocytes drug effects, Ovulation Induction methods, Progestins, Oocyte Donation
- Published
- 2024
- Full Text
- View/download PDF
21. Maternale Hämodynamik in hypertensiven Schwangerschaftserkrankungen unter antihypertensiver Therapie (HyperDip-Studie)
- Author
-
Palmrich, P, additional, Haase, N, additional, Sugulle, M, additional, Kalafat, E, additional, Khalil, A, additional, Schirwani-Hartl, N, additional, Haberl, C, additional, Herrmann, C, additional, and Binder, J, additional
- Published
- 2023
- Full Text
- View/download PDF
22. OP11.07: Machine learning prediction model for gestational diabetes in twin pregnancies: a population based study
- Author
-
Mustafa, H., primary, Kalafat, E., additional, Heydari, M., additional, Nunge, R., additional, and Khalil, A., additional
- Published
- 2023
- Full Text
- View/download PDF
23. Bedeutung angiogener Marker in Schwangerschaften mit intrauteriner Wachstumsrestriktion
- Author
-
Palmrich, P, additional, Kalafat, E, additional, Pateisky, P, additional, Schirwani-Hartl, N, additional, Haberl, C, additional, Herrmann, C, additional, Khalil, A, additional, and Binder, J, additional
- Published
- 2023
- Full Text
- View/download PDF
24. OP11.01: Machine learning prediction of gestational hypertension and pre‐eclampsia in twin pregnancies: a population‐based study
- Author
-
Mustafa, H., primary, Kalafat, E., additional, Heydari, M., additional, Nunge, R., additional, and Khalil, A., additional
- Published
- 2023
- Full Text
- View/download PDF
25. Prognostic value of angiogenic markers in pregnancies with fetal growth restriction
- Author
-
Palmrich, P., primary, Kalafat, E., additional, Pateisky, P., additional, Schirwani‐Hartl, N., additional, Haberl, C., additional, Herrmann, C., additional, Khalil, A., additional, and Binder, J., additional
- Published
- 2023
- Full Text
- View/download PDF
26. First‐trimester choroid‐plexus‐to‐lateral‐ventricle disproportion and prediction of subsequent ventriculomegaly
- Author
-
Prasad, S., primary, Di Fabrizio, C., additional, Eltaweel, N., additional, Kalafat, E., additional, and Khalil, A., additional
- Published
- 2023
- Full Text
- View/download PDF
27. Longitudinal assessment of spiral and uterine arteries in normal pregnancies using novel ultrasound tools
- Author
-
Horgan, R., primary, Sinkovskaya, E., additional, Saade, G., additional, Kalafat, E., additional, Rice, M. M., additional, Heeze, A., additional, and Abuhamad, A., additional
- Published
- 2023
- Full Text
- View/download PDF
28. P-777 Can endometrial compaction predict live birth/ongoing pregnancy rates in assisted reproductive technology cycles? A systematic review and meta-analysis
- Author
-
Turkgeldi, E, primary, Kalafat, E, additional, Yildiz, S, additional, Keles, I, additional, Ata, B, additional, and Bozdag, G, additional
- Published
- 2023
- Full Text
- View/download PDF
29. Are systemic progesterone levels in true natural cycle euploid frozen embryo transfers with luteal phase support predictive for ongoing pregnancy rates?
- Author
-
Lawrenz, B, primary, Ata, B, additional, Kalafat, E, additional, Melado, L, additional, ElKhatib, I, additional, Del Gallego, R, additional, and Fatemi, H, additional
- Published
- 2023
- Full Text
- View/download PDF
30. Association of 'normal' early follicular FSH concentrations with unexpected poor or suboptimal response when ovarian reserve markers are reassuring: a retrospective cohort study.
- Author
-
Del Gallego R, Lawrenz B, Ata B, Kalafat E, Melado L, Elkhatib I, and Fatemi H
- Subjects
- Female, Humans, Retrospective Studies, Treatment Outcome, Ovulation Induction, Follicle Stimulating Hormone, Anti-Mullerian Hormone, Fertilization in Vitro, Ovarian Reserve physiology
- Abstract
Research Question: Are basal FSH measurements, when elevated within its normal range, useful for assessing overall ovarian response and predicting unexpected poor or suboptimal ovarian response?, Design: Retrospective cohort study of ovarian stimulation cycles., Results: A total of 1058 ovarian stimulation cycles (891 first, 167 repeated) were included. Anti-Müllerian hormone (AMH) values were categorized into four (0 to ≤0.6, >0.6 to ≤1.2, >1.2 to ≤3.0, >3.0 to ≤6.25 ng/ml) and basal FSH levels into four groups (<25th percentile: >3.5 to 6.1 IU/ml; 25-75th percentile: >6.1 to ≤8.5 IU/ml; >75-90th percentile: >8.5 to ≤9.9 IU/ml; >90th percentile: >9.9 to ≤12.5 IU/ml). Including only first cycles, a significant independent effect of basal FSH on retrieved cumulus-oocyte complex (COC) count was seen for all basal FSH categories (>90th, >75 to ≤90th, >25 to ≤75th compared with ≤25th percentile, P < 0.001, P = 0.001 and P = 0.007, respectively), when adjusted for age, body mass index (BMI), AMH, antral follicle count (AFC), starting dose and gonadotrophin type. Including only first cycles, patients aged 35 years or older with AFC of 5 or above and AMH 1.2 ng/ml or above, showed significantly higher odds of unexpected poor or suboptimal response if they had higher basal FSH values. Most prominently in the above 90th percentile group (OR 8.64, 95% CI 2.84 to 28.47 compared with <25th percentile) but lower categories (>25th to ≤75th percentile: OR 3.04, 95% CI 1.42 t 6.99; >75th to ≤90th percentile: OR 3.47, 95% CI 1.28 to 9.83 compared with ≤25th percentile) also showed a significant association after adjusting for age, AMH, BMI, AFC, dose, and gonadotrophin type. In patients with a second cycle, an increase in FSH levels in the second round compared with the first was associated with fewer retrieved COCs (estimate: -0.44, 95% CI -0.44 to -0.05, P = 0.027). This effect was adjusted for changes in age, FSH, AFC, starting dose, stimulation duration and change in medication type., Conclusions: Basal FSH is independently associated with overall ovarian response. Moreover, it is associated with unexpected poor or suboptimal response in patients, who would fulfill POSEIDON group 2 criteria after oocyte retrieval., (Copyright © 2023 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Should the trigger to oocyte retrieval interval be different in progestin-primed ovarian stimulation cycles?
- Author
-
Ata B, Cakar A, Türkgeldi E, Yildiz S, Keles İ, and Kalafat E
- Subjects
- Female, Humans, Adult, Pregnancy, Gonadotropin-Releasing Hormone, Retrospective Studies, Ovulation Induction methods, Chorionic Gonadotropin, Fertilization in Vitro methods, Pregnancy Rate, Progestins pharmacology, Oocyte Retrieval
- Abstract
Research Question: Does the trigger to oocyte retrieval interval (TORI) affect oocyte maturation rates differently in progestin-primed ovarian stimulation (PPOS) and gonadotrophin-releasing hormone (GnRH) antagonist cycles?, Design: This was a retrospective cohort study. The interaction between the stimulation protocol and TORI was assessed in a linear mixed effects multivariable regression analysis with oocyte maturation rate as the dependent variable, and stimulation protocol (GnRH antagonist or PPOS), age (continuous), gonadotrophin type (FSH or human menopausal gonadotrophin), trigger (human chorionic gonadotrophin [HCG] or GnRH agonist), TORI (continuous) and days of stimulation (continuous) as the independent variables. Oocyte maturation rate was defined as number of metaphase II oocytes/number of cumulus-oocyte complexes retrieved. The maturation rate was calculated per cycle and treated as a continuous variable., Results: A total of 473 GnRH antagonist and 205 PPOS cycles (121 conventional PPOS and 84 flexible PPOS) were analysed. The median (quartiles) female age was 36 (32-40) years. Of these cycles, 493 were triggered with HCG and 185 with a GnRH agonist. The TORI ranged between 33.6 and 39.1 h, with a median (quartiles) of 36.2 (36-36.4) hours. Maturation rates were similar between fixed PPOS, flexible PPOS and antagonist cycles (median 80%, 75% and 75%, respectively, P = 0.15). There was no significant interaction between the stimulation protocols and TORI for oocyte maturation., Conclusions: PPOS cycles do not seem to require a longer TORI than GnRH antagonist cycles., (Copyright © 2023 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Progestin-primed ovarian stimulation: for whom, when and how?
- Author
-
Ata B and Kalafat E
- Subjects
- Pregnancy, Female, Humans, Embryo Transfer methods, Reproductive Techniques, Assisted, Pregnancy Rate, Gonadotropin-Releasing Hormone, Fertilization in Vitro methods, Retrospective Studies, Progestins pharmacology, Progestins therapeutic use, Ovulation Induction methods
- Abstract
Progestin-primed ovarian stimulation (PPOS) is being increasingly used for ovarian stimulation in assisted reproductive technology. Different progestins have been used with similar success. The available studies suggest a similar response to ovarian stimulation with gonadotrophin-releasing hormone (GnRH) analogues. Any differences in the duration of stimulation or gonadotrophin consumption are minor and clinically insignificant. PPOS has the advantage of oral administration and lower medication costs than GnRH analogues. As such it is clearly more cost-effective for fertility preservation and planned freeze-all cycles, but when fresh embryo transfer is intended PPOS can be less cost-effective depending on the local direct and indirect costs of the additional initial frozen embryo transfer cycle. Oocytes collected in PPOS cycles have similar developmental potential, including blastocyst euploidy rates. Frozen embryo transfer outcomes of PPOS and GnRH analogue cycles seem to be similar in terms of both ongoing pregnancy/live birth rates and obstetric and perinatal outcomes. While some studies have reported lower cumulative live birth rates with PPOS, they have methodological issues, including arbitrary definitions of the cumulative live birth rate. PPOS has been used in all patient types (except progesterone receptor-positive breast cancer patients) with consistent results and seems a patient friendly and cost-effective choice if a fresh embryo transfer is not intended., (Copyright © 2023 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
33. Maternal haemodynamics in Hypertensive Disorders of Pregnancy under antihypertensive therapy (HyperDiP): study protocol for a prospective observational case-control study
- Author
-
Palmrich, P., Haase, N., Sugulle, M., Kalafat, E., Khalil, A., and Binder, J.
- Subjects
Cardiovascular and Metabolic Diseases - Abstract
INTRODUCTION: Hypertensive disorders of pregnancy (HDP) are associated with a high incidence of maternal and perinatal morbidity and mortality. HDP, in particular pre-eclampsia, have been determined as risk factors for future cardiovascular disease. Recently, the common hypothesis of pre-eclampsia being a placental disorder was challenged as numerous studies show evidence for short-term and long-term cardiovascular changes in pregnancies affected by HDP, suggesting a cardiovascular origin of the disease. Despite new insights into the pathophysiology of HDP, concepts of therapy remain unchanged and evidence for improved maternal and neonatal outcome by using antihypertensive agents is lacking. METHODS AND ANALYSIS: A prospective observational case-control study, including 100 women with HDP and 100 healthy controls, which will assess maternal haemodynamics using the USCOM 1A Monitor and Arteriograph along with cardiovascular markers (soluble fms-like kinase 1/placental-like growth factor, N-terminal pro-B type natriuretic peptide) in women with HDP under antihypertensive therapy, including a follow-up at 3 months and 1 year post partum, will be conducted over a 50-month period in Vienna. A prospective, longitudinal study of cardiovascular surrogate markers conducted in Oslo will serve as a comparative cohort for the Vienna cohort of haemodynamic parameters in pregnancy including a longer follow-up period of up to 3 years post partum. Each site will provide a dataset of a patient group and a control group and will be assessed for the outcome categories USCOM 1A measurements, Arteriograph measurements and Angiogenic marker measurements. To estimate the effect of antihypertensive therapy on outcome parameters, ORs with 95% CIs will be computed. Longitudinal changes of outcome parameters will be compared between normotensive and hypertensive pregnancies using mixed-effects models. ETHICS AND DISSEMINATION: Ethical approval has been granted to all participating centres. Results will be published in international peer-reviewed journals and will be presented at national and international conferences.
- Published
- 2023
34. Evaluation of immunogenicity and reactogenicity of COVID-19 vaccines in pregnant women.
- Author
-
Blakeway H, Amin-Chowdhury Z, Prasad S, Kalafat E, Ismail M, Abdallah FN, Rezvani A, Amirthalingam G, Brown K, Le Doare K, Heath PT, Ladhani SN, and Khalil A
- Subjects
- Female, Humans, Pregnancy, COVID-19 Vaccines, SARS-CoV-2, Cohort Studies, Longitudinal Studies, RNA, Messenger, mRNA Vaccines, COVID-19, Vaccines
- Abstract
Objective: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy is associated with increased risk of adverse maternal and perinatal outcomes. Vaccines are highly effective at preventing severe coronavirus disease 2019 (COVID-19), but there are limited data on COVID-19 vaccines in pregnancy. This study aimed to investigate the reactogenicity and immunogenicity of COVID-19 vaccines in pregnant women when administered according to the 12-week-interval dosing schedule recommended in the UK., Methods: This was a cohort study of pregnant women receiving COVID-19 vaccination between April and September 2021. The outcomes were immunogenicity and reactogenicity after COVID-19 vaccination. Pregnant women were recruited by phone, e-mail and/or text and were vaccinated according to vaccine availability at their local vaccination center. For immunogenicity assessment, blood samples were taken at specific timepoints after each dose to evaluate nucleocapsid protein (N) and spike protein (S) antibody titers. The comparator group comprised non-pregnant female healthcare workers in the same age group who were vaccinated as part of the national immunization program in a contemporaneous longitudinal cohort study. Longitudinal changes in serum antibody titers and association with pregnancy status were assessed using a two-step regression approach. Reactogenicity assessment in pregnant women was undertaken using an online questionnaire. The comparator group comprised non-pregnant women aged 18-49 years who had received two vaccine doses in primary care. The association of pregnancy status with reactogenicity was assessed using logistic regression analysis., Results: Overall, 67 pregnant women, of whom 66 had received a mRNA vaccine, and 79 non-pregnant women, of whom 50 had received a mRNA vaccine, were included in the immunogenicity study. Most (61.2%) pregnant women received their first vaccine dose in the third trimester, while 3.0% received it in the first trimester and 35.8% in the second trimester. SARS-CoV-2 S-antibody geometric mean concentrations after mRNA vaccination were not significantly different at 2-6 weeks after the first dose but were significantly lower at 2-6 weeks after the second dose in infection-naïve pregnant compared with non-pregnant women. In pregnant women, prior infection was associated with higher antibody levels at 2-6 weeks after the second vaccine dose. Reactogenicity analysis included 108 pregnant women and 116 non-pregnant women. After the first dose, tiredness and chills were reported less commonly in pregnant compared with non-pregnant women (P = 0.043 and P = 0.029, respectively). After the second dose, feeling generally unwell was reported less commonly (P = 0.046) in pregnant compared with non-pregnant women., Conclusions: Using an extended 12-week interval between vaccine doses, antibody responses after two doses of mRNA COVID-19 vaccine were found to be lower in pregnant compared with non-pregnant women. Strong antibody responses were achieved after one dose in previously infected women, regardless of pregnancy status. Pregnant women reported fewer adverse events after both the first and second dose of vaccine. These findings should now be addressed in larger controlled studies. © 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology., (© 2022 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.)
- Published
- 2022
- Full Text
- View/download PDF
35. Metformin for Prevention of Hypertensive Disorders of Pregnancy in Women With Gestational Diabetes or Obesity: Systematic Review and Meta-analysis of Randomized Trials
- Author
-
Kalafat, E., Sukur, Y. E., Abdi, A., Thilaganathan, B., and Khalil, A.
- Published
- 2019
- Full Text
- View/download PDF
36. OP08.10: Point‐of‐care ultrasound and undiagnosed breech presentation
- Author
-
Knights, S., primary, Prasad, S., additional, Kalafat, E., additional, Dadali, A., additional, Harlow, F., additional, and Khalil, A., additional
- Published
- 2022
- Full Text
- View/download PDF
37. OP08.02: Point‐of‐care ultrasound versus routine third trimester ultrasound and undiagnosed breech presentation
- Author
-
Knights, S., primary, Prasad, S., additional, Kalafat, E., additional, Dadali, A., additional, Harlow, F., additional, and Khalil, A., additional
- Published
- 2022
- Full Text
- View/download PDF
38. OP02.03: Maternal hemodynamic function and angiogenic markers after COVID‐19 infection in pregnancy
- Author
-
Schirwani, N., primary, Palmrich, P., additional, Pateisky, P., additional, Tschanun, L., additional, Khalil, A., additional, Kalafat, E., additional, Kiss, H., additional, and Binder, J., additional
- Published
- 2022
- Full Text
- View/download PDF
39. Adverse neonatal outcome in twin pregnancy complicated by small-for-gestational age: twin vs singleton reference charts.
- Author
-
Briffa C, Di Fabrizio C, Kalafat E, Giorgione V, Bhate R, Huddy C, Richards J, Shetty S, and Khalil A
- Subjects
- Birth Weight, Cohort Studies, Female, Fetal Growth Retardation diagnosis, Fetal Growth Retardation epidemiology, Fetal Weight, Gestational Age, Humans, Infant, Newborn, Infant, Small for Gestational Age, Pregnancy, Pregnancy Outcome epidemiology, Retrospective Studies, Ultrasonography, Prenatal, Infant, Newborn, Diseases, Pregnancy, Twin
- Abstract
Objective: The use of twin-specific vs singleton growth charts in the assessment of twin pregnancy has been controversial. The aim of this study was to assess whether a diagnosis of small-for-gestational age (SGA) made using twin-specific estimated-fetal-weight (EFW) and birth-weight (BW) charts is associated more strongly with adverse neonatal outcomes in twin pregnancies, compared with when the diagnosis is made using singleton charts., Methods: This was a cohort study of twin pregnancies delivered at St George's Hospital, London, between January 2007 and May 2020. Twin pregnancies complicated by intrauterine death of one or both twins, fetal aneuploidy or major abnormality, twin-twin transfusion syndrome or twin anemia-polycythemia sequence and those delivered before 32 weeks' gestation, were excluded. SGA was defined as EFW or BW below the 10
th centile, and was assessed using both twin-specific and singleton EFW and BW charts. The main study outcome was composite adverse neonatal outcome. Mixed-effects logistic regression analysis with random pregnancy-level intercepts was used to test the association between SGA classified using the different charts and adverse neonatal outcome., Results: A total of 1329 twin pregnancies were identified, of which 913 (1826 infants) were included in the analysis. Of these pregnancies, 723 (79.2%) were dichorionic and 190 (20.8%) were monochorionic. Using the singleton charts, 33.3% and 35.7% of pregnancies were classified as SGA based on EFW and BW, respectively. The corresponding values were 5.9% and 5.6% when using the twin-specific charts. Classification as SGA based on EFW using the twin charts was associated significantly with composite adverse neonatal outcome (odds ratio (OR), 4.78 (95% CI, 1.47-14.7); P = 0.007), as compared with classification as appropriate-for-gestational age (AGA). However, classification as SGA based on EFW using the singleton standard was not associated significantly with composite adverse neonatal outcome (OR, 1.36 (95% CI, 0.63-2.88); P = 0.424). Classification as SGA based on EFW using twin-specific standards provided a significantly better model fit than did using the singleton standard (likelihood ratio test, P < 0.001). When twin-specific charts were used, classification as SGA based on BW was associated significantly with a 9.3 times increased odds of composite adverse neonatal outcome (OR, 9.27 (95% CI, 2.86-30.0); P < 0.001). Neonates classified as SGA according to the singleton BW standard but not according to the twin-specific BW standards had a significantly lower rate of composite adverse neonatal outcome than did AGA twins (OR, 0.24 (95% CI, 0.07-0.66); P = 0.009)., Conclusions: The singleton charts classified one-third of twins as SGA, both prenatally and postnatally. Infants classified as SGA according to the twin-specific charts, but not those classified as SGA according to the singleton charts, had a significantly increased risk of adverse neonatal outcome compared with infants classified as AGA. This study provides further evidence that twin-specific charts perform better than do singleton charts in the prediction of adverse neonatal outcome in twin pregnancies. The use of these charts may reduce misclassification of twins as SGA and improve identification of those that are truly growth restricted. © 2021 International Society of Ultrasound in Obstetrics and Gynecology., (© 2021 International Society of Ultrasound in Obstetrics and Gynecology.)- Published
- 2022
- Full Text
- View/download PDF
40. Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy
- Author
-
Prasad, S, Kalafat, E, Blakeway, H, Townsend, R, O'Brien, P, Morris, E, Draycott, T, Thangaratinam, S, Le Doare, K, Ladhani, S, von Dadelszen, P, Magee, LA, Heath, P, and Khalil, A
- Abstract
Safety and effectiveness of COVID-19 vaccines during pregnancy is a particular concern affecting vaccination uptake by this vulnerable group. Here we evaluated evidence from 23 studies including 117,552 COVID-19 vaccinated pregnant people, almost exclusively with mRNA vaccines. We show that the effectiveness of mRNA vaccination against RT-PCR confirmed SARS-CoV-2 infection 7 days after second dose was 89·5% (95% CI 69·0-96·4%, 18,828 vaccinated pregnant people, I2 = 73·9%). The risk of stillbirth was significantly lower in the vaccinated cohort by 15% (pooled OR 0·85; 95% CI 0·73-0·99, 66,067 vaccinated vs. 424,624 unvaccinated, I2 = 93·9%). There was no evidence of a higher risk of adverse outcomes including miscarriage, earlier gestation at birth, placental abruption, pulmonary embolism, postpartum haemorrhage, maternal death, intensive care unit admission, lower birthweight Z-score, or neonatal intensive care unit admission (p > 0.05 for all). COVID-19 mRNA vaccination in pregnancy appears to be safe and is associated with a reduction in stillbirth.
- Published
- 2022
41. Maternal and perinatal outcomes of SARS‐CoV ‐2 infection in unvaccinated pregnancies during Delta and Omicron waves
- Author
-
Birol Ilter, P., primary, Prasad, S., additional, Mutlu, M. A., additional, Tekin, A. B., additional, O'Brien, P., additional, von Dadelszen, P., additional, Magee, L. A., additional, Tekin, S., additional, Tug, N., additional, Kalafat, E., additional, and Khalil, A., additional
- Published
- 2022
- Full Text
- View/download PDF
42. Adverse neonatal outcome in twin pregnancy complicated by small-for-gestational age: twin vs singleton reference charts
- Author
-
Briffa, C, Di Fabrizio, C, Kalafat, E, Giorgione, V, Bhate, R, Huddy, C, Richards, J, Shetty, S, and Khalil, A
- Subjects
female genital diseases and pregnancy complications ,reproductive and urinary physiology - Abstract
Objective\ud The use of twin-specific vs singleton growth charts in the assessment of twin pregnancy has been controversial. The aim of this study was to assess whether a diagnosis of small-for-gestational age (SGA) made using twin-specific estimated-fetal-weight (EFW) and birth-weight (BW) charts is associated more strongly with adverse neonatal outcomes in twin pregnancies, compared with when the diagnosis is made using singleton charts.\ud \ud Methods\ud This was a cohort study of twin pregnancies delivered at St George's Hospital, London, between January 2007 and May 2020. Twin pregnancies complicated by intrauterine death of one or both twins, fetal aneuploidy or major abnormality, twin–twin transfusion syndrome or twin anemia–polycythemia sequence and those delivered before 32 weeks' gestation, were excluded. SGA was defined as EFW or BW below the 10th centile, and was assessed using both twin-specific and singleton EFW and BW charts. The main study outcome was composite adverse neonatal outcome. Mixed-effects logistic regression analysis with random pregnancy-level intercepts was used to test the association between SGA classified using the different charts and adverse neonatal outcome.\ud \ud Results\ud A total of 1329 twin pregnancies were identified, of which 913 (1826 infants) were included in the analysis. Of these pregnancies, 723 (79.2%) were dichorionic and 190 (20.8%) were monochorionic. Using the singleton charts, 33.3% and 35.7% of pregnancies were classified as SGA based on EFW and BW, respectively. The corresponding values were 5.9% and 5.6% when using the twin-specific charts. Classification as SGA based on EFW using the twin charts was associated significantly with composite adverse neonatal outcome (odds ratio (OR), 4.78 (95% CI, 1.47–14.7); P = 0.007), as compared with classification as appropriate-for-gestational age (AGA). However, classification as SGA based on EFW using the singleton standard was not associated significantly with composite adverse neonatal outcome (OR, 1.36 (95% CI, 0.63–2.88); P = 0.424). Classification as SGA based on EFW using twin-specific standards provided a significantly better model fit than did using the singleton standard (likelihood ratio test, P
- Published
- 2022
43. Clinical severity of SARS‐CoV ‐2 infection among vaccinated and unvaccinated pregnancies during the Omicron wave
- Author
-
Birol Ilter, P., primary, Prasad, S., additional, Berkkan, M., additional, Mutlu, M. A., additional, Tekin, A. B., additional, Celik, E., additional, Ata, B., additional, Turgal, M., additional, Yildiz, S., additional, Turkgeldi, E., additional, O'Brien, P., additional, von Dadelszen, P., additional, Magee, L. A., additional, Kalafat, E., additional, Tug, N., additional, and Khalil, A., additional
- Published
- 2022
- Full Text
- View/download PDF
44. Should angiogenic markers be included in diagnostic criteria of superimposed pre‐eclampsia in women with chronic hypertension?
- Author
-
Binder, J., primary, Kalafat, E., additional, Palmrich, P., additional, Pateisky, P., additional, and Khalil, A., additional
- Published
- 2022
- Full Text
- View/download PDF
45. Thrombocytopenia in pregnancy: do the time of diagnosis and delivery route affect pregnancy outcome in parturients with idiopathic thrombocytopenic purpura?
- Author
-
Yuce, T., Acar, D., Kalafat, E., Alkilic, A., Cetindag, E., and Soylemez, F.
- Published
- 2014
- Full Text
- View/download PDF
46. An internally validated prediction model for critical COVID-19 infection and intensive care unit admission in symptomatic pregnant women
- Author
-
Kalafat, E. Prasad, S. Birol, P. Tekin, A.B. Kunt, A. Di Fabrizio, C. Alatas, C. Celik, E. Bagci, H. Binder, J. Le Doare, K. Magee, L.A. Mutlu, M.A. Yassa, M. Tug, N. Sahin, O. Krokos, P. O'brien, P. von Dadelszen, P. Palmrich, P. Papaioannou, G. Ayaz, R. Ladhani, S.N. Kalantaridou, S. Mihmanli, V. Khalil, A.
- Abstract
Background: Pregnant women are at an increased risk of mortality and morbidity owing to COVID-19. Many studies have reported on the association of COVID-19 with pregnancy-specific adverse outcomes, but prediction models utilizing large cohorts of pregnant women are still lacking for estimating the risk of maternal morbidity and other adverse events. Objective: The main aim of this study was to develop a prediction model to quantify the risk of progression to critical COVID-19 and intensive care unit admission in pregnant women with symptomatic infection. Study Design: This was a multicenter retrospective cohort study including 8 hospitals from 4 countries (the United Kingdom, Austria, Greece, and Turkey). The data extraction was from February 2020 until May 2021. Included were consecutive pregnant and early postpartum women (within 10 days of birth); reverse transcriptase polymerase chain reaction confirmed SARS-CoV-2 infection. The primary outcome was progression to critical illness requiring intensive care. The secondary outcomes included maternal death, preeclampsia, and stillbirth. The association between the primary outcome and 12 candidate predictors having a known association with severe COVID-19 in pregnancy was analyzed with log-binomial mixed-effects regression and reported as adjusted risk ratios. All the potential predictors were evaluated in 1 model and only the baseline factors in another. The predictive accuracy was assessed by the area under the receiver operating characteristic curves. Results: Of the 793 pregnant women who were positive for SARS-CoV-2 and were symptomatic, 44 (5.5%) were admitted to intensive care, of whom 10 died (1.3%). The ‘mini-COvid Maternal Intensive Therapy’ model included the following demographic and clinical variables available at disease onset: maternal age (adjusted risk ratio, 1.45; 95% confidence interval, 1.07–1.95; P=.015); body mass index (adjusted risk ratio, 1.34; 95% confidence interval, 1.06–1.66; P=.010); and diagnosis in the third trimester of pregnancy (adjusted risk ratio, 3.64; 95% confidence interval, 1.78–8.46; P=.001). The optimism-adjusted area under the receiver operating characteristic curve was 0.73. The ‘full-COvid Maternal Intensive Therapy’ model included body mass index (adjusted risk ratio, 1.39; 95% confidence interval, 1.07–1.95; P=.015), lower respiratory symptoms (adjusted risk ratio, 5.11; 95% confidence interval, 1.81–21.4; P=.007), neutrophil to lymphocyte ratio (adjusted risk ratio, 1.62; 95% confidence interval, 1.36–1.89; P
- Published
- 2022
47. Effect of the endometrial thickness on the live birth rate: insights from 959 single euploid frozen embryo transfers without a cutoff for thickness.
- Author
-
Ata B, Liñán A, Kalafat E, Ruíz F, Melado L, Bayram A, Elkhatib I, Lawrenz B, and Fatemi HM
- Subjects
- Pregnancy, Female, Humans, Pregnancy Rate, Retrospective Studies, Prospective Studies, Embryo Transfer, Live Birth, Blastocyst pathology, Birth Rate, Fertilization in Vitro
- Abstract
Objective: To investigate whether endometrial thickness (ET) independently affects the live birth rate (LBR) after embryo transfer., Design: Retrospective study., Setting: Private assisted reproductive technology center., Patient(s): A total of 959 single euploid frozen embryo transfers., Intervention(s): Vitrified euploid blastocyst transfer., Main Outcome Measure(s): Live birth rate per embryo transfer., Result(s): The conditional density plots did not demonstrate either a linear relationship between the ET and LBR or a threshold below which the LBR decreased perceivably. Receiver operating characteristic curve analyses did not suggest a predictive value of the ET for the LBR. The area under the curve values were 0.55, 0.54, and 0.54 in the overall, programmed, and natural cycle transfers, respectively. Logistic regression analyses with age, embryo quality, day of trophectoderm biopsy, body mass index, and ET did not suggest an independent effect of the ET on the LBR., Conclusion(s): We did not identify a threshold of the ET that either precluded live birth or under which the LBR decreases perceivably. Common practice of cancelling embryo transfers when the ET is <7 mm may not be justified. Prospective studies, in which the management of the transfer cycle would not be altered by ET, would provide higher-quality evidence on the subject., (Copyright © 2023 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
48. Maternal haemodynamics in Hypertensive Disorders of Pregnancy under antihypertensive therapy (HyperDiP): study protocol for a prospective observational case-control study.
- Author
-
Palmrich P, Haase N, Sugulle M, Kalafat E, Khalil A, and Binder J
- Subjects
- Infant, Newborn, Female, Pregnancy, Humans, Antihypertensive Agents therapeutic use, Case-Control Studies, Prospective Studies, Longitudinal Studies, Placenta, Hemodynamics, Observational Studies as Topic, Pre-Eclampsia drug therapy, Hypertension, Pregnancy-Induced drug therapy
- Abstract
Introduction: Hypertensive disorders of pregnancy (HDP) are associated with a high incidence of maternal and perinatal morbidity and mortality. HDP, in particular pre-eclampsia, have been determined as risk factors for future cardiovascular disease. Recently, the common hypothesis of pre-eclampsia being a placental disorder was challenged as numerous studies show evidence for short-term and long-term cardiovascular changes in pregnancies affected by HDP, suggesting a cardiovascular origin of the disease. Despite new insights into the pathophysiology of HDP, concepts of therapy remain unchanged and evidence for improved maternal and neonatal outcome by using antihypertensive agents is lacking., Methods and Analysis: A prospective observational case-control study, including 100 women with HDP and 100 healthy controls, which will assess maternal haemodynamics using the USCOM 1A Monitor and Arteriograph along with cardiovascular markers (soluble fms-like kinase 1/placental-like growth factor, N-terminal pro-B type natriuretic peptide) in women with HDP under antihypertensive therapy, including a follow-up at 3 months and 1 year post partum, will be conducted over a 50-month period in Vienna. A prospective, longitudinal study of cardiovascular surrogate markers conducted in Oslo will serve as a comparative cohort for the Vienna cohort of haemodynamic parameters in pregnancy including a longer follow-up period of up to 3 years post partum. Each site will provide a dataset of a patient group and a control group and will be assessed for the outcome categories USCOM 1A measurements, Arteriograph measurements and Angiogenic marker measurements. To estimate the effect of antihypertensive therapy on outcome parameters, ORs with 95% CIs will be computed. Longitudinal changes of outcome parameters will be compared between normotensive and hypertensive pregnancies using mixed-effects models., Ethics and Dissemination: Ethical approval has been granted to all participating centres. Results will be published in international peer-reviewed journals and will be presented at national and international conferences., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2023
- Full Text
- View/download PDF
49. Short-term outcomes of pregnant women with convalescent COVID-19 and factors associated with false-negative polymerase chain reaction test: A prospective cohort study
- Author
-
Sahın, O, Yıldırmak, T, Karacalar, S, Cıftcı, MA, Bagcı, H, Yıldırım, S, Aydın, E, Balcı, BG, Emeklıoglu, C, Genc, S, Eren, M, Mıhmanlı, V, Cıngıllıoglu, B, Khalil, A, and Kalafat, E
- Abstract
Aim\ud To evaluate the clinical factors associated with false-negative RT-PCR results and to report the outcome of a cohort of pregnant women with COVID-19.\ud \ud Methods\ud This cohort study was conducted in a tertiary referral pandemic hospital and included 56 pregnant women. A study including pregnant women with either a laboratory or clinical diagnosis for COVID-19 were included in the study. The primary outcome was clinical factors associated with false-negative RT-PCR results defined as a positive immunoglobulin M assessed by rapid testing in clinically diagnosed patients. Clinical outcomes of laboratory diagnosed patients were also reported.\ud \ud Results\ud In total, 56 women with either RT-PCR or clinical COVID-19 diagnosis were included in the study. Forty-three women either had RT-PCR positivity or IgM positivity. The clinical outcome of these pregnancies was as follows: mean maternal age 27.7, immunoglobulin M positive patients 76.7%, RT-PCR positive patients 55.8%, maternal comorbidities 11.5%, complications in patients below 20 weeks 34.8%, complications in patients above 20 weeks 65.1%, elevated CRP 83.7%, lymphopenia 30.2%, time from hospital admission to final follow-up days 37 and stillbirth 8.3%. The proportion of women who tested positive for SARS-CoV-2 immunoglobulin M was 100% in the RT-PCR positive group and 56.5% in the clinical diagnosis group (P = .002). The symptom onset to RT-PCR testing interval longer than a week (risk ratio: 2.72, 95% CI: 1.14-5.40, P = .003) and presence of dyspnoea (risk ratio: 0.38, 95% CI: 0.14-0.89, P = .035) were associated with false-negative RT-PCR tests. The area under the curve of these parameters predicting false-negative RT-PCR was 0.73 (95% CI: 0.57-0.89).\ud \ud Conclusions\ud Symptomatic women with a negative RT-PCR should not be dismissed as potential COVID-19 patients, especially in the presence of prolonged symptom onset-test interval and in women without dyspnoea.
- Published
- 2021
50. OC17.01: Effect of antihypertensive therapy on pre‐ and postnatal cardiovascular parameters in hypertensive disorders of pregnancy: a human and animal model.
- Author
-
Palmrich, P., Haase, N., Sugulle, M., Kalafat, E., Haberl, C., Schirwani‐Hartl, N., Khalil, A., and Binder, J.
- Subjects
LABORATORY rats ,PREGNANCY in animals ,VASCULAR resistance ,CARDIAC output ,BLOOD pressure - Abstract
This article examines the effects of antihypertensive therapy on cardiovascular parameters in women with hypertensive disorders of pregnancy (HDP) and in a pre-eclamptic rat model. The study found that women with HDP experienced significant impairment of cardiac output, augmentation index, and systemic vascular resistance compared to healthy controls. Antihypertensive therapy improved cardiovascular parameters in women with gestational hypertension but did not have a significant impact on those with pre-eclampsia. The study suggests that current standard therapy for pre-eclampsia may not be sufficient to improve cardiovascular impairment. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.